San Diego, CA -- (SBWIRE) -- 09/28/2017 -- Recently MiMedx Group Inc announced an investigation by the Securities and Exchange Commission. The investigation by the SEC follows an investigation for investors of MiMedx Group Inc (NASDAQ:MDXG) shares concerning possible securities laws violations by MiMedx Group Inc in connection with certain financial statements.

Investors who purchased shares of MiMedx Group Inc (NASDAQ:MDXG), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation for ivnestors was announced by a law firm and focuses on whether certain statements by MiMedx Group Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Marietta, GA based MiMedx Group, Inc. is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone MiMedx Group Inc reported that its annual Total Revenue rose from $187.30 million in 2015 to $245.01 million in 2016 and that its Net Income declined from $29.45 million in 2105 to $11.97 million in 2016. Shares of MiMedx Group Inc (NASDAQ:MDXG) grew from $6.74 per share in May 2016 to as high as $17.36 per share on August 16, 2017

On September 20, 2017, two reports were published alleging, among other things, that MiMedx Group Inc may be engaged in a scheme involving undisclosed third-party transactions and entanglements with distributors to improperly account for revenue and that the Company may be under investigation by the SEC.

Shares of MiMedx Group Inc (NASDAQ:MDXG) shares declined on September 21, 2017 to $11.13 per share.

Those who purchased shares of MiMedx Group Inc (NASDAQ:MDXG), have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com